FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research
FAMM-EUROBAT 2024
ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) — FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share the latest advancements in food allergy and anaphylaxis research.
The event featured impactful sessions, debates, workshops, and plenary discussions, highlighting new evidence and the importance of collaboration in tackling health challenges in food allergy and anaphylaxis.
A standout moment was the inaugural World Anaphylaxis Awareness Day on 21 November, created by EAACI to raise global awareness about the life-threatening condition. Introduced during the Opening Ceremony, this initiative set the tone for an inspiring meeting.
A key highlight was the plenary session where the new food allergy guidelines were presented. Tanya and Nadim Ednan-Laperouse, founders of The Natasha Allergy Research Foundation, delivered a moving testimonial sharing their personal story and advocacy efforts, including Natasha's Law, which mandates clearer allergen labelling to protect food allergy sufferers.
The launch of the EAACI Food Allergy Guidelines marked a clinical milestone, offering comprehensive recommendations to improve patient outcomes. Workshops provided deeper insights into allergen immunotherapy and novel immune mechanisms to enhance treatment effectiveness.
Poster Sessions showcased cutting-edge research, highlighting innovative approaches and practical solutions to advance allergy and immunology care.
FAAM-EUROBAT 2024 provided an exceptional platform for knowledge exchange and networking, fostering collaborations among clinicians, researchers, and patient advocates.
Professor Alexandra Santos, Co-Chair of FAAM-EUROBAT 2024, said:
'This year's EAACI FAAM-EUROBAT conference was a testament to the power of science and collaboration between clinicians, scientists and patients with lived experience. From launching the World Anaphylaxis Awareness Day to unveiling unpublished scientific evidence and launching the new clinical guidelines for managing IgE-mediated food allergy, FAAM-EUROBAT 2024 has set a benchmark in the fight against food allergy and anaphylaxis.'
As the meeting concluded, participants left inspired and equipped with new knowledge to improve patient care. FAAM-EUROBAT 2024 celebrated scientific progress and reinforced the importance of global cooperation in addressing pressing health challenges in food allergy and anaphylaxis.
About EAACI
The European Academy of Allergy and Clinical Immunology is the leading organisation for allergy and clinical immunology professionals. EAACI promotes excellence in clinical care, research, education, and allergy and clinical immunology training.
– https://eaaci.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bahrain News Gazette
08-05-2025
- Bahrain News Gazette
EAACI Hong Kong Allergy School 2025: A Landmark in Global Allergy Education
ZURICH, May 08, 2025 (GLOBE NEWSWIRE) — The European Academy of Allergy & Clinical Immunology (EAACI), in partnership with the Hong Kong Institute of Allergy (HKIA), is proud to announce the inaugural EAACI Hong Kong Allergy School. This significant milestone will unfold in Hong Kong – Asia's World City – a dynamic hub where East meets West, innovation meets tradition, and global minds converge. Under the theme 'East Meets West', the 2025 edition of the Allergy School represents a bold step in fostering cross-continental collaboration in allergy and clinical immunology. By bringing together leading global experts, this flagship event aims to enrich knowledge exchange, advance clinical practices, and inspire innovative solutions to allergy care worldwide. Participants will benefit from a rich, interdisciplinary scientific programme, featuring renowned international faculty and cutting-edge topics across the allergy and immunology spectrum. A special dedicated Chinese-language track will be available, promoting inclusivity and greater accessibility for Chinese-speaking professionals. Attendees will also present their research through oral and poster sessions, connect with industry leaders, and build lasting collaborations within the global allergy community. Prizes will be awarded to top abstracts as selected by EAACI's international panel of experts. In celebration of this milestone, EAACI is offering exclusive benefits: Discounted registration for current EAACI members A complimentary 1-year EAACI membership for registered delegates that are not EAACI members We invite you to submit your abstracts and take advantage of early bird registration, available now. The abstract submission deadline is 31 st May 2025. As we gather to celebrate innovation, partnership, and progress, we also invite you to experience the vibrant city of Hong Kong – its iconic skyline, diverse cuisine, and cultural richness – the perfect setting for this global exchange. Join us in shaping the future of allergy science and care. Your participation will help build a thriving; interconnected network of professionals dedicated to better outcomes for patients everywhere. Explore the programme, register, and plan your visit at: About EAACI The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization dedicated to excellence in allergy and immunology. Learn more at . Contact: [email protected] +41 44 205 55 33 GlobeNewswire Distribution ID 1001095348
Bahrain News Gazette
30-04-2025
- Bahrain News Gazette
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
Recognized for Advancing Global Wound Care Through Innovation and Efficacy AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the 16th Abu Dhabi Wound Care Conference . Media Snippet . Presented during the Opening Ceremony at ADNEC, this recognition by the International Interprofessional Wound Care Group (IIWCG) honors excellence in wound care and spotlights breakthroughs redefining standards in chronic wound management through innovation and efficacy. It is not only an honor for DEBx Medical—it's a tribute to the clinical judgment of many clinicians who continue to put DEBRICHEM® into practice and improve outcomes, even in the most challenging cases. DEBRICHEM®: One Application. First Line. Debridement Solution. With just one 60-second application, DEBRICHEM® eradicates devitalized tissue, infection, and biofilm from chronic wounds, key barriers that prevent healing from progressing. For clinicians, it offers : Rapid, targeted action, reopening the pathway to healing An easy-to-use approach for multifactorial wounds A results-driven practical solution in high-pressure settings For healthcare systems and patients, it enables : Fewer interventions and lower resource use Better patient compliance across different wound etiologies Potential reduced reliance on antibiotics, helping to counter antimicrobial resistance A meaningful step forward in the fight against amputations Backed by scientific evidence, DEBRICHEM® supports clinicians in both advanced hospital settings and remote or resource-limited environments. In a time when healthcare efficiency and antimicrobial resistance are pressing global concerns, innovation like DEBRICHEM® is not just valuable, it's vital. 'It's a moment of shared pride and purpose. This recognition by the IIWCG is an incredible honor, not just for DEBx Medical, but for every clinician and patient who places their trust in innovation. DEBRICHEM® was developed to meet a critical gap in chronic wound care. This award validates the real-world impact our team strives for every day: restoring dignity, preserving limbs, improving lives.'— Bert Quint, CEO, DEBx Medical The award underscores DEBx Medical's commitment to advancing wound care that prioritizes patient progress above all. About DEBx Medical DEBx Medical is a medical technology business dedicated to revolutionizing the management of chronic wounds. It focuses on delivering disruptive and efficient wound care treatments that are easy to use and implement in daily clinical practice: DEBRICHEM® – Innovating The Future of Wound Care For inquiries: DEBx Medical : Chandrita Jaisinghani, [email protected] , +31 85 0878096 GlobeNewswire Distribution ID 1001093124
Bahrain News Gazette
10-04-2025
- Bahrain News Gazette
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) , a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company's strategic and clinical initiatives. 'Amir's appointment as President reflects our commitment to strong, visionary leadership as NeOnc advances its clinical programs,' said Dr. Thomas Chen, CEO of NeOnc. 'His extensive experience in building and scaling companies, coupled with his deep understanding of capital markets and business development, will be instrumental as we move forward.' Heshmatpour brings over 25 years of senior executive and board-level experience in business development, operations, finance, and M&A. He is the founder, chairman, and managing director of AFH Holdings & Advisory, where he has led IPO transactions totaling over $1.5 billion, and private funding and M&A transactions exceeding $5 billion in aggregate value. Previously, Heshmatpour served as Chairman and CEO of Metrophone Telecommunications, which he founded in 1994. Under his leadership, Metrophone completed 17 acquisitions and grew annual revenues to over $100 million during a decade of sustained expansion. He has served on the board of the UCLA Anderson School of Management for more than 12 years, and is a board member of the Make-A-Wish Foundation for the Central Coast and Southern Central Valley of California. 'I'm honored to step into the role of President at such a pivotal time in NeOnc's evolution. By formalizing my day-to-day oversight of Company operations, we're enabling Dr. Chen to focus fully on driving our clinical trials forward, with a specific emphasis on patient enrollment for our lead drug candidates — NEO212, our TMZ bio-conjugate, and NEO100,' said Heshmatpour. 'With our promising drug candidates advancing through clinical development, I'm confident in our ability to deliver significant value to patients, providers, and shareholders alike.' ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100 and NEO212 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit . Important Cautions Regarding Forward Looking Statements All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate,' or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. 'NEO100' is a registered trademark of NeOnc Technologies Holdings, Inc. Company Contact: Patrick Walters Chief Operations Officer NeOnc Technologies Holdings, Inc. [email protected] Investor Relations: Roger Pondel / Laurie Berman PondelWilkinson Inc. (310) 279-5980 [email protected] / [email protected] GlobeNewswire Distribution ID 9419859
